CL
ZVSA

CSS LLC’s ZyVersa Therapeutics ZVSA Stock Holding History

CSS LLC’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-42
Closed -$23K – 919
2022
Q4 		$23K Buy
+42
New +$123K ﹤0.01% 772

Other funds holding ZVSA

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAG
Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

CSS LLC's ZVSA Position: Q1 2023 in Review

CSS LLC sold out of ZyVersa Therapeutics (ZVSA) in Q1 2023, closing a stake of 42 shares — an estimated $23K sold.

CSS LLC first reported a position in ZVSA in Q4 2022 and held it in 1 quarter. The position peaked at $23K in Q4 2022. 5 funds tracked by Wall St. Rank hold ZVSA as of Q1 2023.

  • CSS LLC reported no remaining ZyVersa Therapeutics position as of Q1 2023 after selling out during the quarter.
  • CSS LLC sold 42 ZyVersa Therapeutics shares in Q1 2023, an estimated $23K.
  • CSS LLC first reported a position in ZyVersa Therapeutics in Q4 2022 and held it in 1 quarter.
  • CSS LLC's ZyVersa Therapeutics position peaked at $23K in Q4 2022.
  • 5 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q1 2023.

Based on CSS LLC's 13F filing for Q1 2023, filed 15 May 2023.